Elutia Inc. (NASDAQ:ELUT – Get Free Report) was the recipient of a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 25,665 shares, a decline of 39.8% from the May 31st total of 42,627 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 112,225 shares, the days-to-cover ratio is presently 0.2 days.
Wall Street Analysts Forecast Growth
ELUT has been the subject of several research reports. Wall Street Zen raised Elutia from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. Weiss Ratings lowered Elutia from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, June 17th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $6.00.
Check Out Our Latest Research Report on Elutia
Institutional Investors Weigh In On Elutia
Elutia Price Performance
Elutia stock traded up $0.02 during midday trading on Thursday, reaching $0.97. The stock had a trading volume of 1,041 shares, compared to its average volume of 170,343. Elutia has a twelve month low of $0.50 and a twelve month high of $2.64. The firm has a market cap of $41.37 million, a price-to-earnings ratio of 1.12 and a beta of 0.85. The firm’s fifty day simple moving average is $1.04 and its two-hundred day simple moving average is $0.98.
Elutia (NASDAQ:ELUT – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The business had revenue of $3.11 million for the quarter, compared to the consensus estimate of $3.00 million.
About Elutia
Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.
The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.
Read More
- Five stocks we like better than Elutia
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.
